Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Superinvestors holding GANX, Q2 2026
1 superinvestor reports holding Gain Therapeutics, Inc. on Form 13F, worth $1.15M in total. Weight is Gain Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Greenlight CapitalDavid Einhorn | <0.1% | 566,130 | $1.15M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of GANX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2024
1 superinvestor holding at quarter end
- Reduced
- Greenlight Capital (−3.8%)
Q3 2023
1 superinvestor holding at quarter end
- Added
- Greenlight Capital (+7.7%)